000			02321nam a22002537a 4500
999			_c12571 _d12571
001			MED 2022 0004
003			PILC
005			20240720153319.0
008			230619b xxu||||| |||| 00| 0 eng d
040			_beng _cFEU-NRMF MEDICAL LIBRARY _erda
041			_aenglish
050			_aMED 2022 0004
245			_aThe Use of QRISK3 VS framingham in the estimation of cardiovascular disease risk in patients with systematic lupus erythematosus : _ba retrospective cohort study / _cKayla Pamela B. de la Cerna.
260			_aFairview, Quezon City: _bDepartment of Internal Medicine, FEU-NRMF, _c2022.
300			_billustrations, tables; _c(in folder) _ewith flash drive (soft copy).
336			_2rdacontent _atext
337			_2rdamedia _aunmediated
338			_2rdacarrier _avolume
504			_aIncludes appendices and bibliographical references.
520			_aAbstract: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients will systematic lupus enrythematosus (SLE). Studies have shown that SLE patient have a higher risk of developing cardiovascular diseases compared to the general population. Multiple prediction tools such as the Framingham Risk Score (FRS) has been used for primary prevention of CVD event. However, some studies reported that FRS has been shown to underestimate the risk in patients with SLE. In this retrospective study, we investigated and compared the use of QRISK and FRS in the estimation of cardiovascular events among patients with SLE. A total of 100 patients fulfilled the American College of Rheumatology criteria were included. At the end of the study, we report that patients with SLE had female preponderance. The traditional CVD risk factors, higher BMI and hypertension were commonly observed. The comparison of Framingham and QRISK3 in predicting risk of CVD events among SLE patients, results of the present study indicates that QRISK3 identified four times as many SLE patients with high CVD risk than Framingham. It is recommended that a multi-center study should be done to increase the sample size. Moreover, a prospective cross sectional study was also recommended to allow investigators to have a long term follow up with the CVD events.
521			_aRESDM
700			_ade la Cerna, Kayla Pamela B., MD. _eauthor
942			_2lcc _cRU